Trial snapshot
- Formal name: Checkpoint Inhibition in Pediatric Hepatocellular Carcinoma
- Trial type: Includes fibrolamellar carcinoma
- Phase: Phase II
- Recruitment status: Active, Recruiting
- Eligible ages: Up to 30 years
- Location: Boston, MA (Dana‑Farber Cancer Institute), plus sites in California, Ohio, and Texas
- ClinicalTrials.gov ID: NCT04134559
Overview
This phase II clinical trial is studying an immunotherapy drug (pembrolizumab or KEYTRUDA) as a possible treatment for pediatric hepatocellular carcinoma. It is enrolling patients with all types of hepatocellular carcinoma, including fibrolamellar. In this research study, the investigators plan to investigate whether pediatric patients with hepatocellular carcinoma experience stable disease or other response to pembrolizumab.
Trial details and eligibility
Enrollment in this study is open to patients up to age 30. The study’s principal investigator is Dr. Allison O’Neill of the Dana-Farber Cancer Institute. More details and contact information can be found at: https://clinicaltrials.gov/study/NCT04134559.
Dr. Allison O’Neill, the principal investigator of the trial, discusses key aspects of this study and the role of immunotherapy in FLC treatment in the video segment below:
Please visit clinicaltrials.gov for a comprehensive list of active trials.
The Fibrolamellar Cancer Foundation does not provide medical advice. We provide website users with information to help them better understand their health conditions and current approaches towards diagnosis, treatment and supportive care. Always seek the advice of your physician or other qualified healthcare provider.